Video

Justin Gover

Justin Gover, Chief Executive Officer of Greenwich Biosciences, discusses the FDA's planned review of Epidiolex, a formulation of cannabidiol, for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.


 

Limelight Video

Next Article:

Related Articles